Our Science

Moving discoveries

Ludwig's integrated technology development programs, led by Jonathan Skipper, are built to seamlessly move the most promising breakthroughs from the laboratory to clinical testing. We don't wait and hope for others to act on our work, we have dedicated teams to manage every step, from drug discovery to the clinic and beyond. At Ludwig, we test our work against the one measure that matters—human benefit.

Go to making discoveries

Start-up companies

Another way Ludwig accelerates discoveries to improve human health is by starting private companies that will focus on a promising breakthrough with commercial potential. The Ludwig Institute typically holds a stake in the venture, providing scientific assistance and potentially generating financial returns to fund additional research.

Several Ludwig-born companies have been acquired by pharmaceutical and biotech companies, increasing the potential patient benefits of our discoveries.

Companies

IOX THERAPEUTICS
iOx Therapeutics was established in 2015 to develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and the University of Oxford’s Weatherall Institute of Molecular Medicine.

ITEOS THERAPEUTICS
iTeos Therapeutics SA launched in 2012 to develop new methods to stimulate the immune system’s ability to attack cancer. Founded by the Ludwig Institute with the de Duve Institute at the Université catholique de Louvain in Belgium, iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship.
Visit website

SERAMETRIX
Serametrix began operations in 2009 to develop and commercialize products based on the Ludwig Institute’s pioneering research into immunological biomarkers for predicting drug response. The tests determine immune reaction to tumor antigens and are of value to clinicians and drug developers alike.
Visit website

RECEPTA BIOPHARMA
Recepta, Brazil’s first oncology start-up company, is pursuing clinical development of targeted antibodies generated by Ludwig investigators, and of second-generation antibodies generated by their scientific staff. In 2007, Recepta initiated the first FDA-registered phase II clinical trial fully conceived and conducted in Brazil.
Visit website

LIFE SCIENCE PHARMACEUTICALS
Life Sciences, established in 2006, is developing three targeted antibodies generated and assessed in clinical trials by the Ludwig Institute. These antibodies are potentially beneficial in treating or diagnosing a variety of cancers. In 2008, Abbott Laboratories acquired exclusive rights to develop one of these antibodies.
Visit website

VEGENICS
Vegenics began in 2006 in collaboration with Licentia Ltd, the technology transfer arm of the University of Helsinki, to develop and commercialize products based on discoveries from the Ludwig Institute's global angiogenesis program. In 2008, Vegenics was acquired by Circadian Technologies Ltd.
Visit website

LYMPHATIX
Lymphatix was created in 2004 with Licentia Ltd to develop and commercialize products based on discoveries from the Ludwig Institute's global angiogenesis program. The company was acquired by Ark Therapeutics Group in 2008.

PIRAMED
LICR started its first company, Piramed Ltd, to develop new cancer therapies based on selective small-molecule inhibitors of phosphatidyl-inositol 3-kinase (PI3K) signal transduction. These inhibitors resulted from research conducted at the former Ludwig Institute Branch in London, with collaborators at Cancer Research UK and the Institute of Cancer Research. In 2008, Piramed was acquired for by the pharmaceutical company Roche.